Market research
ENGN enGene Holdings Inc. Common Stock
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 121M
- P/E ratio
- Not available
- Analyst target
- 3.2857
- Dividend yield
- Not available
- Beta
- -0.27
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- CA29286X1015
- Market cap
- 121M
- P/E ratio
- Not available
- Analyst target
- 3.2857
- Dividend yield
- Not available
- Beta
- -0.27
About
About enGene Holdings Inc. Common Stock
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.
Visit company websiteCommunity
Investor discussion
0 comments
Sign in to join the ENGN discussion.
No comments yet
Start a focused discussion about ENGN.